Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 20, 2019 - Issue 9
Submit an article Journal homepage
372
Views
3
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?

Emanuel RaschiPharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, ItalyCorrespondence[email protected]
View further author information
,
Elisabetta PoluzziPharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, ItalyView further author information
,
Giulio MarchesiniUnit of Metabolic Diseases & Clinical Dietetics, Department of Medical and Surgical Sciences, University of Bologna, Bologna, ItalyView further author information
&
Fabrizio De PontiPharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, ItalyView further author information
Pages 1087-1090 | Received 06 Dec 2018, Accepted 20 Mar 2019, Published online: 28 Mar 2019

References

  • Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in Type 2 Diabetes. N Engl J Med. 2019;380:347–357.
  • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
  • Bailey CJ, Marx N. Cardiovascular protection in type 2 diabetes: insights from recent outcome trials. Diabetes Obes Metab. 2019;21:3–14.
  • Home P. Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia. 2019;62:357–369.
  • Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
  • Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
  • Raschi E, Poluzzi E, Fadini GP, et al. Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough? Diabetes Obes Metab. 2018;20:2711–2723.
  • Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–39.
  • Scholtes RA, van Baar MJB, Lytvyn Y, et al. Sodium glucose cotransporter (SGLT)-2 inhibitors: do we need them for glucose-lowering, for cardiorenal protection or both? Diabetes Obes Metab. 2019. Epub ahead of print. DOI:10.1111/dom.13692
  • Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–2701.
  • Das SR, Everett BM, Birtcher KK, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the american college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2018;72:3200–3223.
  • Giugliano D, Meier JJ, Esposito K. Heart failure and type 2 diabetes: from cardiovascular outcome trials, with hope. Diabetes Obes Metab. 2019. Epub ahead of print. DOI:10.1111/dom.13629
  • Potier L, Roussel R, Velho G, et al. Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use. Diabetologia. 2019. DOI:10.1007/s00125-019-4835-z.
  • Ueda AC, Zarin W, Cardoso R, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register-based cohort study. BMJ. 2018;363:k4365.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.